That said, if these promising results will be confirmed in larger and longer phase-3 RCTs with liver histological endpoints, it is reasonable that GLP-1 RAs will become a suitable treatment option (alone or in combination with other pharmacotherapies) in people with NAFLD or NASH, especially in those who are obese or have T2DM. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.